Cullinan Therapeutics reports positive CLN-978 data at EULAR 2026
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress
June 6, 2026 5:15 AM EDTClinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978Â
Deep, dose-dependent B cell depletion observed in peripheral blood and tissue
Favorable safety profile with single target doses up to 30 µg as well as initial multi-dose regimen
Data from the first RA multi-dose regimen cohort and initial clinical data for velinotamig, a BCMAxCD3 T cell engager, to be shared at Cullinans Immunology Day on June 10
CAMBRIDGE, Mass., June 06, 2026 (GLOBE NEWSWIRE) --... More
